Home » Genomic Testing

Genomic Testing

What is Genetic testing?

Genetic testing, Genomic Testing, is a test to examine a person’s risk of developing hereditary disease or to tailor personalized medication.

The process of analyzing the DNA of cells or tissues to look for genetic changes that may be a sign of a disease such as cancer.

For example, testing mutations in the BRCA gene for early detection or preventing the development of breast cancer.

What is Gene? What is Genome?

Gene is a fragment in the DNA strand that encodes physiological features, for example, eye color.

The genes genes are inherited upon cell division when the DNA molecule replicates, and each new cell receives a copy of the replicated DNA.

Genome is the full system of all the genes in an organism.

In humans, all genes are located on structures called chromosomes. Chromosomes are complexes of DNA and proteins bind to each other.

Almost every cell in the body contains a complete copy of the genome. The genome contains all the information a person needs for development and growth.

The Genome study provides an understanding of how cancer cells are formed and respond to therapy.

People with different genetic will respond differently to a particular drug.

For example, So certain drugs that are not given to people with certain DNA mutations.

What is a Mutation?

Mutation is a change of the DNA sequence in the cell.

Mutations can be caused by errors during cell division, or they can be caused by exposure to substances harmful to DNA (free radicals, asbestos, etc.).

Mutations can be harmful, beneficial, or have no effect.

When they appear in egg or sperm cells, they can be inherited.

Sometimes cancer is seen in families more often than was randomly expected (coincidence). This cancer often occurs at a young age, and may indicate the presence of a genetic mutation that increases the risk of cancer. It also constitutes a sign of environmental factors affecting life in a common environment.

If mutations occur in other types of cells, they are not inherited and are called somatic mutations.

Mutations can lead to cancer or other diseases

When is it important to perform genetic testing?

Why it is important to do genetic testing?

In cancer, personalized medicine uses the patient’s specific disease characteristics and medical background to form a personalized therapy program.

Read our publications on genetic and genomic testing and other innovative treatments for cancer:

Lung cancer – A novel treatment with Sugemalimab

Overview Smoking tobacco products has made lung cancer one of the most common tumors in the world. The prevalence of lung cancer is especially predominant

Breast Cancer - NERLYNX (Neratinib) for Leptomeningeal Metastases

Breast Cancer – NERLYNX for Leptomeningeal Metastases

Overview The spread of cancer cells beyond the original site of the tumor is a very challenging process. When cancer cells of the breast are

Glioblastoma – A New Combination Treatment You Need to Know

Overview Glioblastoma, or GBM, is an aggressive type of tumor that occurs in the brain. Due to the location of this tumor and the limited

Rechallenge Treatment for Metastatic Colorectal Cancer Patients

Overview Over the past few years, researchers have been trying to find new treatment protocols for colorectal cancer by combining anticancer drugs. Fortunately, these efforts

Melanoma – Alrizomadlin, Fast Track Designation for Advanced Disease

Overview The FDA has granted a Fast Track Designation to the novel MDM2-p53 inhibitor named “Alrizomadlin” (APG-115) for the treatment of patients with unresectable or

סרטן קיבה, ושט-קיבה – קיטרודה לחולי הר2+ משפרת יעילות

Gastric and GEJ cancers – Keytruda to HER2+ patients, improves outcomes

Background The first findings of KEYNOTE-811, an ongoing, global phase III trial, found that the addition of Keytruda to Herceptin plus chemotherapy for first-line treatment

Gastric cancer - Adding Bemarituzumab to chemo improves the results

Gastric Cancer – Bemarituzumab Plus Chemo Improves Outcomes

Background Gastric cancer has a new target to attack: FGFR2b. Anew drug, “Bemarituzumab”, targets FGFR2b. When Bemarituzumab was given with chemotherapy, the combination postponed the

Trial – Berzosertib can neutralize the cancer’s ability to repair itself

Berzosertib – Trial Rational Berzosertib is the first to be studied of a new family of treatments. These drugs block a protein involved in DNA

Halaven plus Keytruda for metastatic Triple Negative Breast Cancer

Triple Negative Breast Cancer: Halaven plus Keytruda

About the two study drugs in Triple Negative Breast Cancer Both study drugs are FDA approved. Halaven is approved for advanced breast cancer and Keytruda

Lung cancer and thyroid – First RET+ drug, Retevmo

The FDA has approved Retevmo capsules for the treatment of patients with lung cancer or thyroid cancer harboring RET alterations. This is the first therapy

To check if our service suits your case
We need to talk

Improve therapeutic outcomes, prolong life and quality of life, is our main business.
We support access to and expand cancer treatments beyond the standard of care, with the most advanced and innovative treatment options in the world, personally matching the individual cancer patient’s medical condition and with the support of top tier oncologists.

Article categories

קטגוריות המאמרים

Colorectal Cancer – Krazati with or without Erbitux in Mutated KRAS G12C

Cannabidiol oil failed to overcome palliative care in advanced cancer

Gastric Cancer – Zolbetuximab Prolongs Survival

Sarcoma – Lenvima Plus Halaven in Advanced Disease

Glioblastoma – Radiotherapy Plus Temodar With Nimotuzumab

Colorectal Cancer - Vitamin C Plus Chemo in RAS mutated patients

Colorectal Cancer – Vitamin C in RAS mutated patients

Home » Genomic Testing

Lung cancer – A novel treatment with Sugemalimab

Overview

Smoking tobacco products has made lung cancer one of the most common tumors in the world. The prevalence of lung cancer is especially predominant in men.

Besides chemotherapy and radiation therapy, scientists have been trying to come up with biological treatments that effectively treat advanced cases of lung cancer.

In general, scientists categorize this cancer into two types:

Non-small cell lung cancer (NSCLC) – represents 80–85% of all cases. It is typically milder than SCLS.

Small-cell lung cancer (SCLC) – accounts for 15–20% of all cases. SCLC has a rapid proliferation rate and tends to spread to other tissues of the body. It is quite sensitive to chemotherapeutic agents. However, relapse rates are high due to metastases.

In this article, we will cover the effects of a new drug called Sugemalimab on lung cancer. Before we do that, let us quickly define this drug and explain its mechanism of action.

What is Sugemalimab?

Sugemalimab is a monoclonal antibody that targets the PD-L1 receptors. This drug proved to be effective for advanced stages of NSCLC, according to clinical trials. Mainly, it improves the survival outcomes compared to chemotherapy when used as first-line treatment.

Initially, the drug was discovered by CStone Pharmaceuticals in treating lymphoma, a type of blood cancer.

How does Sugemalimab help?

To conduct this study, researchers assessed 846 patients for eligibility. Only 479 were eligible and were randomly assigned to receive Sugemalimab (320 patients) or placebo (159 patients).

In the interim analysis that checked for the primary endpoint – the time the disease worsens from the start of the treatment, also called Progression-Free Survival (PFS) – researchers met their goals with a large margin. The group that received the treatment had a PFS of 7.8 months, whereas the placebo group had a PFS of 4.9 months.

At 17.8 months into the clinical trial, the PFS of the two groups was as follow:

Sugemalimab group – 9 months
Placebo group – 4.9 months

The most common side effects of Sugemalimab were hematological in nature (e.g., decreased platelet count).

Analyzing these results demonstrates that Sugemalimab plus chemotherapy yield significantly better clinical outcomes compared to placebo plus chemotherapy. The intriguing part about these results is that they are present in all patients with non-squamous metastatic NSCLC, regardless of PD-L1 expression.

The authors of this study believe that Sugemalimab could be a new first-line therapy for squamous and non-squamous NSCLC.

Takeaway message

Sugemalimab seems to have a lot of potential in the treatment of advanced non-small cell lung cancer. Speak with your doctor about your eligibility to receive this drug.

Hopefully, this article managed to simplify the mechanism and efficacy of Sugemalimab in treating lung cancer.

To learn more about other treatments of Non Small Lung Cancer, do not hesitate to check our other articles.

Talk to us so see if we can help you to actually get the most advanced treatments

TRIAL•IN Pharma

Because we, do not give up on life!

Contact us 24/7 –

Call center +44.2082.426.039

No Cost service compatibility check
Please fill in the details and we will back to you as soon as possible

Improving therapeutic success, extending life and quality of life are our main business. We extend to metastatic cancer patients and patients with brain tumors, the most advanced treatment options in the world and the best experts in Israel and abroad.

Article categories

Genomic Testing

What is Genetic testing?

What is Gene? What is Genome?

What is a Mutation?

Why it is important to do genetic testing?

קטגוריות המאמרים

Tags

Lung cancer – A novel treatment with Sugemalimab

Overview

What is Sugemalimab?

How does Sugemalimab help?

Takeaway message

Talk to us so see if we can help you to actually get the most advanced treatments

קטגוריות המאמרים

Tags